TAK-242, a TLR4 antagonist, has shown promise as adjunct therapy for thrombocytopenia in sepsis by mitigating LPS-induced systemic inflammation, thus reducing end-organ damage and slowing sepsis progression [119,120,121]. This evidence concerns the gene TLR4 and Sepsis.